文献速递细菌感染、耐药与抗菌药物

复方磺胺甲噁唑相关高钾血症与急性肾损伤风险的真实世界评估

Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study.
PubMed 文献 · Clin Microbiol Infect · 2020-03-25

这项回顾性观察研究基于3年电子病历数据,分析了214例接受复方磺胺甲噁唑治疗的患者。结果显示19.6%发生急性肾损伤(AKI),15.4%发生高钾血症。低基线估算肾小球滤过率(eGFR)、心脏病史及较高基线血钾是独立预测因素,低剂量用药与较低风险相关,早期(2-4天)肌酐和血钾变化可预测后续事件。

要点

  • 复方磺胺甲噁唑相关AKI和高钾血症常见且呈剂量依赖。
  • 用药前应评估肾功能、血钾及心脏病史。
  • 治疗初2-4天监测肌酐和血钾有助于识别易感患者。

核心结论

  • 复方磺胺甲噁唑相关AKI和高钾血症发生率较高且与剂量相关,用药前应评估肾功能、血钾和心脏病史,并在治疗早期监测肌酐和血钾。

研究设计与样本

  • 回顾性观察研究,通过电子健康记录识别3年内(2016年4月1日至2019年3月31日)接受复方磺胺甲噁唑处方的214例患者。

主要发现

  • 214例中42例(19.6%,95%CI 14.6-25.7)符合AKI标准,33例(15.4%,95%CI 11.0-21.1)发生高钾血症。
  • 低基线eGFR(<60 mL/min/1.73 m2,OR 7.78,95%CI 3.57-16.13,p<0.0001)和心脏病(OR 2.40,95%CI 1.17-4.82,p=0.011)预测AKI。
  • 低基线eGFR(<60 mL/min/1.73 m2,OR 6.80,95%CI 3.09-15.06,p<0.0001)和较高基线血钾(p=0.001)预测高钾血症。
  • 低剂量复方磺胺甲噁唑(<1920 mg/d)与较低的AKI和高钾血症风险相关(p=0.007和p=0.019)。
  • 治疗早期(2-4天内)肌酐变化预测AKI(OR 3.65,95%CI 1.73-7.41,p=0.001),早期血钾变化>0.6 mmol/L预测高钾血症(OR 2.47,95%CI 1.14-5.27,p=0.0236)。

临床怎么用

  • 处方复方磺胺甲噁唑前应评估肾功能、血钾和心脏病史。
  • 治疗最初2-4天监测血清肌酐和血钾以识别易感患者。
  • 应使用最低有效剂量以降低AKI和高钾血症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Increasing antimicrobial resistance has renewed interest in older, less used antimicrobials. Cotrimoxazole shows promise; however, hyperkalaemia and acute kidney injury (AKI) are potential complications. Identifying risk factors for and quantification of these events is required for safe use. This study aimed to evaluate predictors of cotrimoxazole-associated AKI and hyperkalaemia in a clinical setting. METHODS: Patients prescribed cotrimoxazole were identified using electronic healthcare records over 3 years (1 April 2016 to 31 March 2019). Individual risk factors were recognized. Serum creatinine and potassium trends were analysed over the subsequent 21 days. AKI and patients with hyperkalaemia were classified using Kidney Disease Improving Global Outcomes (KDIGO) and laboratory criteria. Univariate and multiple logistic regression analyses were performed. RESULTS: Among 214 patients prescribed cotrimoxazole, 42 (19.6%, 95% confidence interval (CI) 14.6-25.7) met AKI criteria and 33 (15.4%, 95% CI 11.0-21.1) developed hyperkalaemia. Low baseline estimated glomerular filtration rate (<60 mL/min/1.73 m2, odds ratio (OR) 7.78, 95% CI 3.57-16.13, p < 0.0001) and cardiac disorders (OR 2.40, 95% CI 1.17-4.82, p 0.011) predicted AKI, while low baseline estimated glomerular filtration rate (<60 mL/min/1.73 m2, OR 6.80, 95% CI 3.09-15.06, p < 0.0001) and higher baseline serum potassium (p 0.001) predicted hyperkalaemia. Low-dose cotrimoxazole (<1920 mg/d) was associated with lower AKI and hyperkalaemia risk (p 0.007 and 0.019 respectively). Early (within the first 2-4 days of therapy) serum creatinine changes predicted AKI (OR 3.65, 95% CI 1.73-7.41, p 0.001), and early serum potassium changes predicted hyperkalaemia (>0.6 mmol/L, OR 2.47, 95% CI 1.14-5.27, p 0.0236). CONCLUSIONS: Cotrimoxazole-associated AKI and hyperkalaemia is frequent and dose dependent. Renal function, serum potassium and preexisting cardiac disorders should be evaluated before prescribing cotrimoxazole. Serum creatinine and potassium monitoring within first 2 to 4 days of treatment to identify susceptible patients is recommended, and the lowest effective dose ought to be prescribed.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Rajput J, Moore LSP, Mughal N, et al. Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study. Clin Microbiol Infect. 2020. PMID: 32220637. doi:10.1016/j.cmi.2020.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。